Trial Profile
A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Leucine/metformin/sildenafil (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Acronyms TRIPLN
- Sponsors NuSirt Biopharma
- 25 Apr 2018 Primary endpoint has not been met. (Change in hepatic fat) as per results published in the Alimentary Pharmacology and Therapeutics
- 25 Apr 2018 Results published in the Alimentary Pharmacology and Therapeutics
- 12 Sep 2017 Status changed from active, no longer recruiting to completed.